Tag: Product of Nature

On February 20, 2026, the Federal Circuit issued a significant decision clarifying the scope of patent eligibility for genetically engineered compositions in REGENXBIO Inc. v. Sarepta Therapeutics, Inc., No. 2024-1408 (Fed. Cir. Feb. 20, 2026). Reversing the District of Delaware, the court held that claims directed to cultured host cells containing recombinant nucleic acid molecules…